Skip to main content
. 2021 Jan 11;11:430. doi: 10.1038/s41598-020-79948-x

Figure 3.

Figure 3

Long-term TM5614 treatment leads to a reduction in circulatory cholesterol and PCSK9 in mice fed a HFHS diet. WT C57BL/6 J male mice fed HFHS diet with and without TM5614. (A) Active PAI-1 levels (ng/mL). (B) Cholesterol distribution on plasma lipoprotein fractions resolved by FPLC from pooled samples (n = 2 for HFHS, n = 3 for HFHS + TM5614) (2-way ANOVA p = 0.03). (C) Quantification of cholesterol in each lipoprotein fraction calculated using area under the curve from the FPLC profile. (D) Hepatic mRNA expression of cholesterol regulatory pathway nodes. (E) Plasma PCSK9 levels (ng/mL). (F) LDLR protein levels from liver lysates (ng LDLR/mg Liver Protein). Values are express as mean ± SEM (n = 7), * p < 0.05, ** p < 0.01, *** p < 0.001.